NOMINATING AGREEMENTNominating Agreement • August 9th, 2019 • IGM Biosciences, Inc. • Pharmaceutical preparations • Delaware
THIS NOMINATING AGREEMENT (this “Agreement”), dated as of June 28, 2019, is by and between IGM Biosciences, Inc., a Delaware corporation (the “Company”) Redmile Biopharma Investments II, L.P., RAF, L.P. and Redmile Strategic Master Fund, LP (each an “Investor” and together, the “Investors”).
NOMINATING AGREEMENTNominating Agreement • August 9th, 2019 • IGM Biosciences, Inc. • Pharmaceutical preparations • Delaware
THIS NOMINATING AGREEMENT (this “Agreement”), dated as of June 28, 2019, is by and between IGM Biosciences, Inc., a Delaware corporation (the “Company”) 667, L.P. and Baker Brothers Life Sciences, L.P. (each an “Investor” and together, the “Investors”).
NOMINATING AGREEMENTNominating Agreement • August 9th, 2019 • IGM Biosciences, Inc. • Pharmaceutical preparations • Delaware
THIS NOMINATING AGREEMENT (this “Agreement”), dated as of June 28, 2019, is by and between IGM Biosciences, Inc., a Delaware corporation (the “Company”) and Haldor Topsøe Holding A/S (the “Investor”).
AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • August 9th, 2019 • IGM Biosciences, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT is made and entered into as of June 28, 2019, by and between IGM BIOSCIENCES, INC., a Delaware corporation (the “Corporation”), and the undersigned holders of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock of the Corporation (the “Investors”).
